Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genmab
Company Location: 1253 COPENHAGEN K G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Georgia, Moldova, Spain
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Central Nervous System Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GCT1056-01 | P1 |
Active, not recruiting |
Central Nervous System Cancer |
2025-12-18 |